Biogen (BIIB)

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

的Biogen Inc. Common Stock（BIIB）股票after-hours的价格今天是，自市场最后关闭以来，反映出NaN%after-hours的变动。该公司市值为$269.92亿，日交易量为股。前一交易日收盘价为 。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买Biogen股票的指南。